Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
03 September 2009 - 11:15PM
PR Newswire (US)
JERUSALEM, September 3 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals Inc. (OTC BB: ORMP.OB) (http://www.oramed.com/), a
developer of alternative drug delivery systems, announced today
that Nadav Kidron, its Chief Executive Officer, is scheduled to
present at the Rodman & Renshaw's 11th Annual Healthcare
Conference on Friday September 11, 2009 at 10:00 a.m. EDT. The
conference will be held at the New York Palace Hotel in New York
City. Nadav Kidron is scheduled to speak in the Fahnestock Salon on
the fifth floor of the hotel. He will discuss Oramed's strategic
initiatives, updates and product pipeline. About Oramed
Pharmaceuticals Oramed Pharmaceuticals is a technology pioneer in
the field of oral delivery solutions for drugs and vaccines
presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented
flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology
is based on over 25 years of research by top research scientists at
Jerusalem's Hadassah Medical Center. The Company's corporate and
R&D headquarters are based in Jerusalem. For more information,
please visit http://www.oramed.com/. Forward-looking statements
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the
progress, timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please
refer to the company's filings with the Securities and Exchange
Commission for a comprehensive list of risk factors that could
cause actual results, performance or achievements of the company to
differ materially from those expressed or implied in such forward
looking statements. The company undertakes no obligation to update
or revise any forward-looking statements. Company and Investor
Relations Contacts: Oramed Pharmaceuticals Tara Horn USA:
+1-646-240-4193 Office: +972-2-566-0001 Email: DATASOURCE: Oramed
Pharmaceuticals Inc. CONTACT: Company and Investor Relations
Contacts: Oramed Pharmaceuticals, Tara Horn, USA: +1-646-240-4193,
Office: +972-2-566-0001, Email:
Copyright